Verano Holdings Corp banner
V

Verano Holdings Corp
CNSX:VRNO

Watchlist Manager
Verano Holdings Corp
CNSX:VRNO
Watchlist
Price: 5.01 CAD -10.22% Market Closed
Market Cap: CA$1.8B

Relative Value

There is not enough data to reliably calculate the relative value of VRNO.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRNO Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

VRNO Competitors Multiples
Verano Holdings Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Verano Holdings Corp
CNSX:VRNO
1.7B CAD 1.4 -4.5 5.5 12.5
US
Eli Lilly and Co
NYSE:LLY
923.3B USD 14.2 44.7 30.2 32.2
US
Johnson & Johnson
NYSE:JNJ
582.8B USD 6.2 21.7 15.1 18.6
CH
Roche Holding AG
SIX:ROG
252.7B CHF 4.2 19.9 11.8 13.3
UK
AstraZeneca PLC
LSE:AZN
221.8B GBP 5.1 29.3 16.2 22.9
CH
Novartis AG
SIX:NOVN
230.9B CHF 5.3 21.4 13.3 17.1
US
Merck & Co Inc
NYSE:MRK
286.8B USD 4.4 15.7 9.8 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.8 8 9.4
US
Pfizer Inc
NYSE:PFE
152.7B USD 2.4 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
118.7B USD 2.5 16.8 7.1 8.8
P/E Multiple
Earnings Growth PEG
US
V
Verano Holdings Corp
CNSX:VRNO
Average P/E: 22.2
Negative Multiple: -4.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.7
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.7
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.9
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.3
26%
1.1
CH
Novartis AG
SIX:NOVN
21.4
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.7
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
V
Verano Holdings Corp
CNSX:VRNO
Average EV/EBITDA: 42.7
5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.2
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.8
6%
2
UK
AstraZeneca PLC
LSE:AZN
16.2
13%
1.2
CH
Novartis AG
SIX:NOVN
13.3
5%
2.7
US
Merck & Co Inc
NYSE:MRK
9.8
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
1%
8
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
V
Verano Holdings Corp
CNSX:VRNO
Average EV/EBIT: 92.9
12.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.6
7%
2.7
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
22.9
21%
1.1
CH
Novartis AG
SIX:NOVN
17.1
9%
1.9
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
3%
3.1
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett